Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline ; volume:15 ; number:1 ; day:21 ; month:8 ; year:2023 ; pages:1 ; date:12.2023
Alzheimer's research & therapy ; 15, Heft 1 (21.8.2023), 1, 12.2023
- Urheber
-
Bauzon, Justin
Lee, Garam
Cummings, Jeffrey
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-023-01284-9
- URN
-
urn:nbn:de:101:1-2023110607482705870503
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bauzon, Justin
- Lee, Garam
- Cummings, Jeffrey
- SpringerLink (Online service)
Ähnliche Objekte (12)
Repurposed agents in the Alzheimer’s disease drug development pipeline
Alzheimer’s Disease Drug Development Pipeline 2020
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Advances in Alzheimer’s Disease Drug Development
The Alzheimer’s disease drug development landscape
Geroscience and Alzheimer’s Disease Drug Development
Converging multi-modality datasets to build efficient drug repositioning pipelines against Alzheimer’s disease and related dementias
Role of anti-diabetic drugs as therapeutic agents in Alzheimer's disease
Advances in Drug Therapy for Alzheimer’s Disease
Non-drug Therapies for Alzheimer’s Disease: A Review
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
Drug candidates in clinical trials for Alzheimer’s disease
Repurposed agents in the Alzheimer’s disease drug development pipeline
Alzheimer’s Disease Drug Development Pipeline 2020
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Advances in Alzheimer’s Disease Drug Development
The Alzheimer’s disease drug development landscape
Geroscience and Alzheimer’s Disease Drug Development
Converging multi-modality datasets to build efficient drug repositioning pipelines against Alzheimer’s disease and related dementias
Role of anti-diabetic drugs as therapeutic agents in Alzheimer's disease
Advances in Drug Therapy for Alzheimer’s Disease
Non-drug Therapies for Alzheimer’s Disease: A Review
Heterogeneity of Alzheimer’s disease: consequence for drug trials?
Drug candidates in clinical trials for Alzheimer’s disease
Repurposed agents in the Alzheimer’s disease drug development pipeline
Alzheimer’s Disease Drug Development Pipeline 2020
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Advances in Alzheimer’s Disease Drug Development
The Alzheimer’s disease drug development landscape
Geroscience and Alzheimer’s Disease Drug Development
Converging multi-modality datasets to build efficient drug repositioning pipelines against Alzheimer’s disease and related dementias
Role of anti-diabetic drugs as therapeutic agents in Alzheimer's disease
Advances in Drug Therapy for Alzheimer’s Disease
Non-drug Therapies for Alzheimer’s Disease: A Review
Heterogeneity of Alzheimer’s disease: consequence for drug trials?